The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A02 | Drugs for acid related disorders | |
3
|
A02B | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) | |
4
|
A02BA | H2-receptor antagonists | |
5
|
A02BA01 | Cimetidine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 0.8 g | |
| PAREN | Parenteral | 0.8 g |
| Active Ingredient |
|---|
|
Cimetidine is a histamine H2-receptor antagonist which rapidly inhibits both basal and stimulated gastric secretion of acid and reduces pepsin output. It is a reversible, competitive antagonist, and is used as an anti-ulcer drug. |
| Document | Type | Information Source | |
|---|---|---|---|
| Tagamet 200mg Tablets | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| ULCOMET Film coated tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.